Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer Business
Neuraly Announces Completion of Enrollment in Phase 2 Clinical Trial of NLY01 in Patients with Parkinson's Disease Business
Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund Business